الولايات المتحدة · منصات وبيانات · The Motley Fool

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

نشره The Motley Fool · الولايات المتحدة منذ 1 س

The company's gene-editing-focused platform looks promising.

اقرأ المقال كاملًا على The Motley Fool سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.fool.com)

يستحق القراءة أيضًا

Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Lula, Bolsonaro rally supporters on final day before Brazil presidential runoff

First Interstate BancSystem: 3 Key Takeaways for Long-Term Investors

Bank of America resets Tesla forecast as Robotaxi miles double